This Long position is from Monday at 9:30 am at which my group is holding positions at $0.16 We are planning to buy as many shares in the red zone and hold. Regardless if price does not reach $0.40 by Friday at 9:30 am. We are still going to hold this stock in our portfolio for a minimum of 3 quarters. The goal here is patience and steady growth. We look to see...
There has not been much good news on this stock lately, but looks like it is trying to make a recovery today. We will be watching this stock for a possible continuation trade tomorrow.
this is what I would prefer to see going forward next week. we need to stay above with the trend and break through those supports. main one is .18 for some reason, once that it gone then it is off to the races!
SELLAS intends to use the net proceeds from the offering to commence a pivotal Phase 3 trial for its lead clinical candidate, galinpepimut-S (“GPS”), as a monotherapy in acute myeloid leukemia patients following second complete remission and to continue its Phase 1/2 basket type trial of GPS in combination with pembrolizumab, as well as for general corporate...
POSITIVE DATA RELEASED ON PHASE SELLAS AnnounceS Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S. KEEP ON WATCH FOR SOME VERY POSITIVE MOVES.
SHORT INTEREST 13.2%
AVERAGE ANALYSTS PRICE TARGET $8.75
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
COMPANY PROFILE
SELLAS is a clinical-stage biopharmaceutical company...
SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
SLS
